OVs preferentially replicate within cancer cells and induce their death, while sparing healthy cells. They also infect tumor-associated endothelial cells, leading to breakdown of tumor vasculature and subsequent necrosis of uninfected tumor cells. In cancer cells, OVs rely on signaling pathways to establish infection and exploit defective anti-viral immune responsiveness to evade immune surveillance. The definition of “onco-lysis” is tumor destruction.
OV with cancer immunotherapy is a combined therapeutic approach. The administered oncolytic virus (OV) attacks the cancer cells, leaving normal human cells untouched. As a result this treatment has no significant side effects. Furthermore, OV combined with other therapies is a promising approach with potential to extend survival time and even cure, while quality of life is maintained.
Approbation as doctor: Witten Herdecke University – 1991
Specialist of Radiology- 2011
Specialist of Radiotherapy- 2014
Specialist of Palliative Medicine- 2017
Diploma in Complementary Medicine
Tersteegenstr. 9 · 40474 Düsseldorf
Tel. 0211 / 4302-0 · Fax 0211 / 4302 2009
Link to the Rules of Professional Practice:
Gesetze / Verordnungen – Ärztekammer Nordrhein (aekno.de)